Akeso's Ligufalimab Shows Strong Phase II Data in Frontline AML
Event summary
- Akeso's Phase II trial of ligufalimab in combination with azacitidine and venetoclax showed an 80.0% objective response rate vs. 66.7% in the control arm for frontline AML patients.
- Median duration of composite complete remission (CRc) was 10.4 months in the ligufalimab arm vs. 6.5 months in the control arm.
- Median overall survival (mOS) not yet reached in the ligufalimab arm vs. 8.3 months in the control arm.
- Ligufalimab received Orphan Drug Designation from the U.S. FDA for AML treatment.
- Akeso is advancing ligufalimab clinical development programs across hematologic malignancies and solid tumors.
The big picture
Akeso's Phase II data for ligufalimab in frontline AML positions the drug as a potential new standard of care, particularly for patients ineligible for intensive chemotherapy. The results come at a time when anti-CD47 therapies are gaining traction, with several competitors also advancing in the space. Akeso's ability to leverage these data to secure regulatory approvals and expand into solid tumors will be critical to its long-term competitive positioning.
What we're watching
- Regulatory Pathway
- Whether the Phase II data will accelerate ligufalimab's path to regulatory approval in AML.
- Clinical Development
- The pace at which Akeso advances ligufalimab into Phase III trials for both hematologic malignancies and solid tumors.
- Competitive Positioning
- How Akeso differentiates ligufalimab in the crowded anti-CD47 space.
Related topics